

January 24, 2025

SMS Lifesciences India Limited

Registered & Corporate Office:

Plot No. 19-III, Road No. 71,

Opp. Bharatiya Vidya Bhavan Public School, Jubilee Hills, Hyderabad - 500 096, Telangana, INDIA.

Tel: +91-040-6628 8888, Fax: +91-40-2355 1401

CIN: L74930TG2006PLC050223

Email: info@smslife.in, Website: www.smslife.in

To

BSE Limited,

Listing Department, P J Towers,

Dalal Street,

Mumbai - 400 001.

Scrip Code: 540679

Through: BSE Listing Center

Dear Sir/Madam,

National Stock Exchange of India Limited,

Listing Department, "Exchange Plaza",

Bandra-Kurla Complex, Bandra (E),

Mumbai - 400 051.

Trading Symbol: SMSLIFE

Through: NEAPS Portal

SUB: UPDATE ON "US-FDA" INSPECTION OF MATERIAL SUBSIDIARY.

REF: Regulation 30(9) of SEBI (Listing Obligations & Disclosure Requirements) Regulation, 2015.

We are glad to inform that <u>United States Food and Drug Administration (USFDA)</u> has conducted an inspection of <u>Mahi Drugs Private Limited (Material Subsidiary)</u> at its API manufacturing facility located at Plot No.82, Jawaharlal Nehru Pharma City Parawada Vishakhapatnam – 531019, from 20th January, 2025 to 24th January, 2025.

"THE INSPECTION WAS CLOSED WITH NO OBSERVATION"

Kindly take the same on record and suitably disseminate it to all concerned.

ences Ino

Hyderabad

For SMS Lifesciences India Limited

Trupti Ranjan Mohanty

Company Secretary